Literature DB >> 27885851

Is anti-inflammatory radiotherapy an effective treatment in trochanteritis?

Izaskun Valduvieco1, Albert Biete1, Luis A Moreno2, Xavier Gallart3, Angels Rovirosa1, Jordi Saez2, Carlos Plana4, Pilar Peris4.   

Abstract

OBJECTIVE: To evaluate the analgesic efficacy of low-dose radiotherapy in refractory cases of trochanteritis.
METHODS: We evaluated a total of 60 consecutive patients who received low-dose radiotherapy to achieve an anti-inflammatory and analgesic effect for recurrent trochanteritis following scarce response to conventional therapy. All patients were evaluated at baseline (prior to radiotherapy) and at 1 and 4 months after radiotherapy and then yearly thereafter for pain assessment using a visual analogue scale (VAS) and to determine the administration of analgesic treatment.
RESULTS: An improvement in the symptomatology was observed in 62% of the patients with a significant reduction in the VAS (8 ± 2 vs 4 ± 2; p < 0.0001), which was largely maintained until the second evaluation at 4 months. In the cases responding to radiotherapy, the probability of maintaining improvement beyond 24 months was 70%.
CONCLUSION: Low-dose anti-inflammatory radiation may be used in the treatment of the recurrent cases of relapse or no response of trochanteritis to conventional treatments, with a high probability of remission of pain. These preliminary results indicate the need for evaluating the use of radiotherapy in patients with trochanteritis refractory to conventional treatment in a long-term controlled study. Advances in knowledge: Radiotherapy provides effective analgesic treatment for patients refractory to standard treatment for trochanteritis.

Entities:  

Mesh:

Year:  2016        PMID: 27885851      PMCID: PMC5605027          DOI: 10.1259/bjr.20160520

Source DB:  PubMed          Journal:  Br J Radiol        ISSN: 0007-1285            Impact factor:   3.039


  19 in total

1.  [Incidence of tuberculous trochanteritis].

Authors:  A Z SORKIN
Journal:  Probl Tuberk       Date:  1958

2.  Radiotherapy of non-malignant disorders: where do we stand?

Authors:  Jan Willem Leer; Paul van Houtte; Heinrich Seegenschmiedt
Journal:  Radiother Oncol       Date:  2007-05-08       Impact factor: 6.280

Review 3.  Anti-inflammatory effects of low-dose radiotherapy. Indications, dose, and radiobiological mechanisms involved.

Authors:  M Arenas; S Sabater; V Hernández; A Rovirosa; P C Lara; A Biete; J Panés
Journal:  Strahlenther Onkol       Date:  2012-08-22       Impact factor: 3.621

4.  Low-dose radiotherapy selectively reduces adhesion of peripheral blood mononuclear cells to endothelium in vitro.

Authors:  P M Kern; L Keilholz; C Forster; R Hallmann; M Herrmann; M H Seegenschmiedt
Journal:  Radiother Oncol       Date:  2000-03       Impact factor: 6.280

5.  Evaluation of radiation treatment of painful conditions of the locomotor system. A double blind study.

Authors:  I Goldie; B Rosengren; E Moberg; E Hedelin
Journal:  Acta Radiol Ther Phys Biol       Date:  1970-08

6.  Corticosteroid injections for greater trochanteric pain syndrome: a randomized controlled trial in primary care.

Authors:  Aaltien Brinks; Rogier M van Rijn; Sten P Willemsen; Arthur M Bohnen; Jan A N Verhaar; Bart W Koes; Sita M A Bierma-Zeinstra
Journal:  Ann Fam Med       Date:  2011 May-Jun       Impact factor: 5.166

7.  Evaluation of glucocorticosteroid injection for the treatment of trochanteric bursitis.

Authors:  M I Shbeeb; J D O'Duffy; C J Michet; W M O'Fallon; E L Matteson
Journal:  J Rheumatol       Date:  1996-12       Impact factor: 4.666

8.  Risk of radiation-induced malignancy with heterotopic ossification prophylaxis: a case-control analysis.

Authors:  Arshin Sheybani; Mindi J TenNapel; William D Lack; Patrick Clerkin; Daniel E Hyer; Wenqing Sun; Geraldine M Jacobson
Journal:  Int J Radiat Oncol Biol Phys       Date:  2014-05-03       Impact factor: 7.038

9.  Low and moderate doses of ionizing radiation up to 2 Gy modulate transmigration and chemotaxis of activated macrophages, provoke an anti-inflammatory cytokine milieu, but do not impact upon viability and phagocytic function.

Authors:  R Wunderlich; A Ernst; F Rödel; R Fietkau; O Ott; K Lauber; B Frey; U S Gaipl
Journal:  Clin Exp Immunol       Date:  2015-01       Impact factor: 4.330

Review 10.  Radiotherapy for non-malignant disorders: state of the art and update of the evidence-based practice guidelines.

Authors:  M H Seegenschmiedt; O Micke; R Muecke
Journal:  Br J Radiol       Date:  2015-05-08       Impact factor: 3.039

View more
  4 in total

Review 1.  Modulating the Antioxidant Response for Better Oxidative Stress-Inducing Therapies: How to Take Advantage of Two Sides of the Same Medal?

Authors:  Priyanka Shaw; Naresh Kumar; Maxime Sahun; Evelien Smits; Annemie Bogaerts; Angela Privat-Maldonado
Journal:  Biomedicines       Date:  2022-03-31

Review 2.  Radiotherapy CT-based contouring atlas for non-malignant skeletal and soft tissue disorders: a practical proposal from Spanish experience.

Authors:  Beatriz Alvarez; Angel Montero; Ovidio Hernando; Raquel Ciervide; Juan Garcia; Mercedes Lopez; Mariola Garcia-Aranda; Xin Chen; Ines Flores; Emilio Sanchez; Jeannette Valero; Alejandro Prado; Rosa Alonso; Leyre Alonso; Pedro Fernandez-Leton; Carmen Rubio
Journal:  Br J Radiol       Date:  2021-08-01       Impact factor: 3.629

3.  Megavoltage Radiotherapy for the Treatment of Degenerative Joint Disease in Dogs: Results of a Preliminary Experience in an Italian Radiotherapy Centre.

Authors:  Federica Rossi; Simona Cancedda; Vito Ferdinando Leone; Carla Rohrer Bley; Paola Laganga
Journal:  Front Vet Sci       Date:  2018-04-10

4.  Low-Dose Radiotherapy Ameliorates Advanced Arthritis in hTNF-α tg Mice by Particularly Positively Impacting on Bone Metabolism.

Authors:  Lisa Deloch; Anja Derer; Axel J Hueber; Martin Herrmann; Georg Andreas Schett; Jens Wölfelschneider; Jonas Hahn; Paul-Friedrich Rühle; Willi Stillkrieg; Jana Fuchs; Rainer Fietkau; Benjamin Frey; Udo S Gaipl
Journal:  Front Immunol       Date:  2018-09-18       Impact factor: 7.561

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.